Recurrence‐free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate

BACKGROUND: Tigilanol tiglate (TT) is a novel small molecule approved by the European Medicines Agency for intratumoral treatment of mast cell tumors (MCTs) in dogs. In a randomized controlled clinical efficacy and safety study in the United States, 85 of 116 dogs that received a single TT injection...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Pamela D., Campbell, Justine E., Brown, Graham, Johannes, Chad M., Reddell, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848364/
https://www.ncbi.nlm.nih.gov/pubmed/33350511
http://dx.doi.org/10.1111/jvim.16018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848364/
https://www.ncbi.nlm.nih.gov/pubmed/33350511
http://dx.doi.org/10.1111/jvim.16018

Ejemplares similares